Aptose Biosciences Files 2024 10-K
Ticker: APTOF · Form: 10-K · Filed: Mar 28, 2025 · CIK: 882361
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
Aptose Biosciences filed its 2024 10-K. Key deals include Hanmi Pharma supply agreement & Newbridge warrants.
AI Summary
Aptose Biosciences Inc. filed its 2024 10-K on March 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is involved in biological products. Key financial instruments mentioned include the 2022 ATM Offering, Newbridge Warrants, and a Supply Agreement with Hanmi Pharmaceuticals Co. Ltd.
Why It Matters
This filing provides a comprehensive overview of Aptose Biosciences' financial health and operational activities for the fiscal year 2024, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company's focus on biological products and its history of name changes suggest potential volatility and the need for careful investor due diligence.
Key Numbers
- 20241231 — Fiscal Year End (The period covered by the 10-K filing.)
- 20250328 — Filing Date (The date the 10-K was officially submitted to the SEC.)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Filer of the 10-K
- Lorus Therapeutics Inc. (company) — Former name of Aptose Biosciences Inc.
- Imutec Pharma Inc. (company) — Former name of Aptose Biosciences Inc.
- Hanmi Pharmaceuticals Co. Ltd. (company) — Party to a Supply Agreement
- Newbridge Warrants (dollar_amount) — Financial instrument mentioned
- 2022 ATM Offering (dollar_amount) — Financial instrument mentioned
FAQ
What is the primary business of Aptose Biosciences Inc.?
Aptose Biosciences Inc. is involved in biological products, specifically with the SIC code 2836 for Biological Products (No Diagnostic Substances).
What were Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. (name change effective 20140905) and prior to that, Imutec Pharma Inc. (name change effective 19970113).
What is the significance of the '2022 ATM Offering' mentioned in the filing?
The '2022 ATM Offering' is a financial instrument or program related to Aptose Biosciences Inc. that was active between 2024-01-01 and 2024-05-30.
Who is Aptose Biosciences Inc. supplying products to under the 'Supply Agreement'?
Aptose Biosciences Inc. has a 'Supply Agreement' with Hanmi Pharmaceuticals Co. Ltd., as indicated for the period ending 2024-12-31.
What is the context of 'Newbridge Warrants' in this filing?
Newbridge Warrants are mentioned in relation to Aptose Biosciences Inc., with a share price measurement input noted as of 2024-12-31.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding Aptose Biosciences Inc. (APTOF).